Z-Medica

ABOUT US

Leading the Hemorrhage Control Market

Z-Medica, a leader in the hemorrhage control category, works closely with customers to develop innovative products and solutions. With a relentless concentration on smart growth and ongoing product development, Z-Medica is a company focused on hemorrhage control for healthcare providers, military personnel, first responders and consumers around the world.

Guided by Experience and Expertise
Z-Medica has assembled a management team to bring its innovative bleeding control products to market around the world.

Click here   to learn more.

A Clear Vision Enabled by a Focused Plan
For more than a decade, Z-Medica has saved lives and improved medical outcomes by developing new tools to control bleeding. Today, Z-Medica builds on its market leadership with ongoing research, product enhancements, brand building and customer insights. With customers throughout the world and ongoing investment, Z-Medica is determined to solidify its position as a hemorrhage control brand of choice.

Positioned and Funded for Growth
DW Healthcare Partners (DWHP) is Z-Medica’s majority shareholder. DWHP is a healthcare-focused private equity firm dedicated to identifying, nurturing and growing ideas and companies. With DWHP’s investment, Z-Medica has focused on new and innovative products, research and development, growing its healthcare sales team and establishing an international presence.

More than a Decade of Invention and Category Leadership
Z-Medica was founded in 2002 after Apollo Space Program Engineer Frank Hursey discovered a novel hemostatic agent. Mr. Hursey saw the potential value of his discovery and, after partnering with Bart Gullong, they set out to ensure that this innovative product was in the hands of anyone who could use it to save lives. While new and revolutionary products have replaced the original zeolite granular product, the desire to bring leading-edge hemostatic innovation to the world lives on.

As a testament to QuikClot’s efficacy, the U.S. Department of Defense’s Committee on Tactical Combat Casualty Care (CoTCCC) recommends QuikClot Combat Gauze® as the hemostatic dressing of choice for compressible hemorrhage not amenable to tourniquet use.1

1. Tactical Combat Casualty Care Guidelines 2 June 2014. http://www.usaisr.amedd.army.mil/pdfs/TCCC_Guidelines_140602.pdf. Accessed March 25, 2015.

12.July.2017

FDA Grants De Novo Clearance for Z-Medica’s QuikClot Control+

 Z-Medica, LLC announces that QuikClot<sup>®</sup> Control+™ has been cleared for use by the US Food and Drug Administration (FDA) under the de novo classification process and is designated as a Class II medical device.

READ MORE ›

06.July.2017

Z-Medica Supports Disabled Veterans Program at UConn School of Business

Z-Medica, LLC, announces today that they are supporting the Entrepreneurship Bootcamp for Veterans with Disabilities (EBV) program at the University of Connecticut (UConn) School of Business.

READ MORE ›

VISIT OUR PRODUCT SITE

Quikclot
Click Here
All trademarks herein are registered trademarks of their respective owners. ©2015 Z-Medica, LLC.
All rights reserved.